Filip K. Knop

GIP did not prevent #hypoglycaemia following excess prandial insulin and physical activity after meal ingestion in males with type 1 #diabetes #T1D …ubs.pericles-prod.literatumonline.com/doi/10.1111/do…

🧠Meet Dr. Liva Krogh (@Metabolcenter), co-investigator & grant recipient of the #EFSD/ @novonordisk A/S Programme for #Diabetes Research in 🇪🇺. Their project investigated how the incretin hormones GIP & GLP-1 act on tissues outside the pancreas. More 👉 europeandiabetesfoundation.org/programmes.html

Don't throw away those sneakers just yet #Exercise cell.com/trends/endocri…

Today, @HannahVigh et al. unleash a freely available and searchable database of the human intestinal transcriptome - an atlas of the expression of 19,739 genes from 16 sites along the intestinal tract. Check out the landscape of your favourite gene here: rnaseq.gubra.dk

When you eat, for how long vs. how much. The pursuit for differentiated outcomes continues medrxiv.org/content/10.110…

🌍 For Half of Humanity: Why we need action on obesity Obesity is one of the defining global health and equity challenges of our time. Today, over 1 billion people live with obesity, and without bold action, 4 billion - half of the world’s population - will be affected by overweight or obesity by 2035. This campaign is our urgent call to action in the lead-up to the 2025 UN High-Level Meeting on Non-Communicable Diseases (HLM on NCDs). Our goal is clear: to secure global recognition of obesity as a chronic disease, drive equitable access to care, and catalyse multisectoral solutions. Obesity doesn’t just impact individuals - it fuels a wider crisis of non-communicable diseases including diabetes, heart disease and cancer. And it’s not just a high-income country issue - 88% of future obesity cases will occur in low- and middle-income countries. But we have the tools to act: proven public health policies, emerging treatments, and growing political momentum. The HLM must our moment to demand action. Join us in demanding: ✅ Obesity recognised as a disease in the HLM Political Declaration ✅ Commitment to WHO recommendations & Acceleration Plan ✅ People with lived experience at the heart of global solutions 🌐 Visit our website to explore campaign materials, take action, and learn why this moment matters. We have #4BillionReasons to act. 🔗 worldobesity.org/HLM4 #4BillionReasons #HalfOfHumanity

Here the authors propose that gut #microbiota derived peptides exhibit potential for prevention and treatment of human metabolic disorders nature.com/articles/s4156…

And you thought #metformin lowered glucose via the liver? Here loss-of-function and gain-of-function studies suggest that VMH Rap1 is indispensable for the antidiabetic effects of metformin in mice #diabetes science.org/doi/10.1126/sc…

A new comprehensive review of the proglucagon-derived peptides #disbetes #obesity #shortbowelsyndrome journals.physiology.org/doi/abs/10.115…

Adult & Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study ➡️Still more to learn on trajectories of single antibody positivity… however stage 2 T1D and progression more defined in adults or children diabetesjournals.org/care/article-a…

🚶‍♂️🚶‍♀️How many steps a day for better health? Meta-analysis of 57 studies 7,000 steps/day associated with ⬇️ risk of: 🩺 All-cause mortality ↓47% ❤️ CVD mortality ↓47% 🧠 Dementia ↓38% 😔 Depression ↓22% 🎗️ Cancer mortality ↓37% 🤕 Falls ↓28% thelancet.com/journals/lanpu…

A 7 day treatment period in humans with type 1 diabetes shows dapagliflozin increases plasma ketone concentrations without affecting the secretion of GLP-1, glucagon or somatostatin. link.springer.com/article/10.100… @DiabetologiaJnl

Roles for VAMP-8 in GLP-1R recycling in beta cells diabetesjournals.org/diabetes/artic…

Studies in mice reveal that LEAP2 analogs have the potential to enhance the efficacy of glucagon-like peptide 1 receptor agonism and support durable #weightloss diabetesjournals.org/diabetes/artic…

#PRESS: At #ADA2025, Novo Nordisk is sharing the full phase 3 study results in people with overweigh or obesity, and overweight or obesity and type 2 diabetes respectively. Both studies simultaneously published in The New England Journal of Medicine. Read the full press release

The Banting Award for scientific achievement to Professor Steven Kahn. A stellar career with scientific leadership across multiple domains #diabetes A poignant celebration unfolds #ADA2025 @AmDiabetesAssn

The vehicle associated phosphoprotein REPS1 identified as a convergence point for #insulin and #exercise signaling, presenting a potential therapeutic target for treating individuals with #insulin resistance @CellRepMed cell.com/cell-reports-m…

GDF15 is still a mystery hormone: Trends in Endocrinology & Metabolism Now finally out in print! cell.com/trends/endocri…

Go with the flow-endogenous GIP and splanchnic blood flow in humans diabetesjournals.org/diabetes/artic…

MARCH2, an E3 ubiquitin ligase, safeguards against metabolic dysfunction-associated #fattyliver disease. By promoting FASN degradation, MARCH2 reduces #hepatic #lipogenesis and steatosis, highlighting a potential therapeutic avenue for #MAFLD. 🔗sciencedirect.com/science/articl…